Barclays’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-7,268
| Closed | -$31K | – | 3936 |
|
|
2021
Q3 | $31K | Sell |
7,268
-1,943
| -21% | -$8.29K | ﹤0.01% | 3511 |
|
|
2021
Q2 | $49K | Buy |
9,211
+8,472
| +1,146% | +$45.1K | ﹤0.01% | 3403 |
|
|
2021
Q1 | $3K | Buy |
739
+734
| +14,680% | +$2.98K | ﹤0.01% | 3810 |
|
|
2020
Q4 | $0 | Sell |
5
-4,500
| -100% | – | ﹤0.01% | 3752 |
|
|
2020
Q3 | $15K | Sell |
4,505
-6,552
| -59% | -$21.8K | ﹤0.01% | 3522 |
|
|
2020
Q2 | $37K | Sell |
11,057
-1,186
| -10% | -$3.97K | ﹤0.01% | 3475 |
|
|
2020
Q1 | $46K | Sell |
12,243
-10,988
| -47% | -$41.3K | ﹤0.01% | 3135 |
|
|
2019
Q4 | $140K | Buy |
23,231
+5,685
| +32% | +$34.3K | ﹤0.01% | 3330 |
|
|
2019
Q3 | $131K | Sell |
17,546
-46,654
| -73% | -$348K | ﹤0.01% | 3260 |
|
|
2019
Q2 | $870K | Buy |
64,200
+58,502
| +1,027% | +$793K | ﹤0.01% | 2426 |
|
|
2019
Q1 | $31K | Sell |
5,698
-26,732
| -82% | -$145K | ﹤0.01% | 3812 |
|
|
2018
Q4 | $96K | Buy |
32,430
+15,758
| +95% | +$46.6K | ﹤0.01% | 2987 |
|
|
2018
Q3 | $136K | Buy |
16,672
+1,272
| +8% | +$10.4K | ﹤0.01% | 3258 |
|
|
2018
Q2 | $150K | Sell |
15,400
-1,094
| -7% | -$10.7K | ﹤0.01% | 2897 |
|
|
2018
Q1 | $143K | Buy |
16,494
+6,944
| +73% | +$60.2K | ﹤0.01% | 3005 |
|
|
2017
Q4 | $119K | Buy |
9,550
+3,723
| +64% | +$46.4K | ﹤0.01% | 2924 |
|
|
2017
Q3 | $49K | Buy |
5,827
+5,201
| +831% | +$43.7K | ﹤0.01% | 2954 |
|
|
2017
Q2 | $10K | Sell |
626
-9,774
| -94% | -$156K | ﹤0.01% | 3439 |
|
|
2017
Q1 | $209K | Buy |
+10,400
| New | +$209K | ﹤0.01% | 2478 |
|
|
2016
Q3 | – | Sell |
-371
| Closed | -$3K | – | 4102 |
|
|
2016
Q2 | $3K | Buy |
+371
| New | +$3K | ﹤0.01% | 3226 |
|